Experts explain the presence and role of EGFR exon 20 insertion mutations in non–small cell lung cancer and highlight the role of molecular profiling. Estelamari Rodriguez, M.D., MPH: Hello, and ...
The diagnostics advisory committee reviewed the evidence available on the clinical and cost effectiveness of epidermal growth factor receptor tyrosine kinase (EGFR‑TK) mutation testing to inform first ...
EGFR mutation testing is crucial for NSCLC treatment, but global disparities exist in access to comprehensive molecular diagnostics. Third-generation inhibitors and combination regimens improve ...
DEAR DR. ROACH: I am a 73-year-old female. A recent blood test returned an eGFR (estimated glomerular filtration rate) of 59. My physician’s nurse told me that the test was normal. When I asked her ...
May 14, 2008 — The blocking of epidermal growth-factor receptors (EGFR) to treat non-small-cell lung cancer is becoming increasingly common, but there is considerable debate about when to initiate ...
The systematic review was carried out to identify evidence on the technical performance and clinical effectiveness of the different options available to detect epidermal growth factor receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback